UNSPSC 51261602: Butaxamine or butoxamine

This classification denotes a beta-adrenergic blocking agent with the molecular formula C15H25NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 0NM31M53PW, chemically known as benzenemethanol, .alpha.-(1-((1,1-dimethylethyl)amino)ethyl)-2,5-dimethoxy-, (r*,s*)-, (+/-)- but generally known as butoxamine, which bears US NIH Compound Identifier 134495. SMILES: CC(C(C1=C(C=CC(=C1)OC)OC)O)NC(C)(C)C.

UNSPSC 51261602 Butaxamine or butoxamine is a Commodity code that captures pharmaceutical products and chemical compounds procured by state and local health agencies, though recent solicitations show limited direct alignment with the code's nominal scope. State and local governments use this code primarily for pharmaceutical inventory procurement, particularly through county health departments and state health and human services commissions. The Seminole County, Florida solicitation (IFB 60459723LAS) demonstrates procurement of naloxone and drug deactivation systems for community health initiatives, with quarterly deliveries and fixed-fee pricing structures; vendors must meet standard compliance requirements including drug-free workplace certification, E-Verify authorization, and specified insurance coverages, with contracts typically structured as two-year terms with one-year renewal options.

Geographic activity is concentrated in the Southeast and Texas, with Seminole County, Florida conducting a competitive bid for 1,900 units of naloxone and 800 drug deactivation systems annually (response deadline July 26, 2023), and the Texas Health and Human Services Commission issuing an exploratory Request for Information (RFI HHS0017013, posted April 3, 2026) to assess vendor capabilities for direct-to-manufacturer prescription programs. The Texas RFI represents preliminary market intelligence rather than a formal solicitation and does not establish budget or award values. Neither recent opportunity explicitly designates set-asides for disadvantaged enterprises. The code shows sparse recent activity aligned with its nominal scope; the mismatch between butaxamine/butoxamine chemistry and the naloxone and pharmaceutical-logistics focus of these solicitations suggests that state and local procurement offices may be applying the code inconsistently or that meaningful pharmaceutical commodity activity under this specific code designation remains limited in current market activity.